Survey Finds Varied Views on Value of Multiple Sclerosis Therapies
February 21st 2017Population-level judgements on the value of therapies to treat multiple sclerosis don’t adequately depict the differences between how providers and payers view value compared with patients and how patients view value different from one another.
Read More
AJMC® in the Press, February 17, 2017
February 17th 2017A news article on using community health records to improve population wellness was included in the Politico Morning eHealth report. RevCycle Intelligence and Patient Engagement HIT both examined the results of a February article on an asthma education program. Health IT Analytics highlighted the findings of a January article that assessed the role of value-based payment in implementing an evidence-based mental health intervention.
Read More
Pembrolizumab Now Approved for First-Line Treatment of Lung Cancer in Europe and the US
February 1st 2017Pembrolizumab (Keytruda) has received green light from the European Commission for the first-line treatment of a select population of adult patients with metastatic non-small cell lung cancer.
Read More
New Target for Treating Glioblastoma May Increase Survival Time
January 26th 2017Researchers from the Peter O’Donnell Jr. Brain Institute and Harold C. Simmons Comprehensive Cancer Center at the University of Texas Southwestern may have found the ultimate drivers of glioblastoma cell proliferation.
Read More